Showing 1 - 7 results of 7 for search 'Ivana Vranic', query time: 0.15s Refine Results
  1. 1
    Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
    Get full text
    Article
    Save to List
    Saved in:
Search Tools: RSS Feed – Email Search